---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-003055"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:53:32.177641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports Q2 results: submits EB613 protocol to FDA, net loss $7.0M, cash $17.3M

## Summary
- Submitted proposed registrational protocol for EB613 (oral PTH) to FDA; expects Type C meeting in H2 2022.
- Finalizing optimized formulation for EB612 (hypoparathyroidism); first-in-human PK study planned H1 2023.
- Net loss $7.0M ($0.24 per share) for six months ended June 30, 2022, vs $4.9M ($0.21) in prior year period.
- Revenue $112k, down from $226k; operating expenses $7.1M, up from $5.0M.
- Cash $17.3M as of June 30, 2022, expected to fund operations through Q2 2023.

## SEC filing metadata
- accession: 0001178913-22-003055
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/0001178913-22-003055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891322003055/zk2228294.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-003055
- JSON: https://secwatch.observer/filing/0001178913-22-003055.json
- Plain text: https://secwatch.observer/filing/0001178913-22-003055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.